Also trades as: 0R0H.L (LSE) · $vol 3M · TN8.DE (XETRA) · $vol 0M · TMO.TO (TSX) · $vol 0M · TMO.NE (NEO) · $vol 0M
TMO NYSE
Thermo Fisher Scientific Inc.
1W: +0.8%
1M: +1.4%
3M: +18.8%
YTD: +15.6%
1Y: +19.8%
3Y: +46.8%
5Y: +17.8%
$693.13
+8.24 (+1.20%)
After Hours: $697.09 (+3.96, +0.57%)
Weekly Expected Move ±4.1%
$619
$647
$674
$701
$729
Credit Risk of going bust: lower than 79% of companies Debt: 14.0% of company value Bonds: $454.1M held by 353 funds, 52 bp over Treasuries → details ▾
Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $7.50 (down 99%), Thermo Fisher Scientific Inc. would be worth roughly what it owes.
Total debt $41.37B against a stock market value of $253.24B.
Distance to default 9.42 (Merton model): prices to 2026-10-26, balance sheet 2026-09-26, debt counted $21.82B (short-term plus half of long-term), stock volatility 29.2%; Altman Z'' 2.15. A ranking and a back-test, not a forecast.
Bond figures are fund-reported marks (SEC N-PORT) as of Jul 2026. How these are computed.
If the stock fell to about $7.50 (down 99%), Thermo Fisher Scientific Inc. would be worth roughly what it owes.
Total debt $41.37B against a stock market value of $253.24B.
Distance to default 9.42 (Merton model): prices to 2026-10-26, balance sheet 2026-09-26, debt counted $21.82B (short-term plus half of long-term), stock volatility 29.2%; Altman Z'' 2.15. A ranking and a back-test, not a forecast.
Bond figures are fund-reported marks (SEC N-PORT) as of Jul 2026. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
📊 Key Metrics
TTM$47B
Revenue
+8.3% YoY
$7B
Net Income
+7.8% YoY
$8B
Free Cash Flow
+24.3% YoY
42.8%
Gross Margin
18.6%
Op. Margin
14.2%
Net Margin
💰 Income Flow
How revenue becomes profit💵 Cash Flow
Where cash goes🏦 Balance Sheet
Assets = Liabilities + Equity📈 Financial Health
Profitability
ROE13.4%
ROA6.5%
ROIC8.6%
Valuation
P/E36.9
P/B4.7
EV/EBITDA26.1
Leverage
Debt/Equity0.76
Current Ratio1.81
Interest Cov.5.8x
Quality Scores
Piotroski F8/9
Altman Z3.32
Beneish M-2.43